Which is better, cagrilintide or pramlintide?
For someone on mealtime insulin who needs better glucose control today, pramlintide is the only lawful choice: it is FDA approved with year long randomized trials, though its effect is modest and it carries a boxed warning for severe hypoglycemia. For weight loss, cagrilintide's evidence is far stronger (10.8% at 26 weeks versus about 3.6 kg placebo corrected at 16 weeks for pramlintide), but it is investigational, has no lawful compounding path, and is prohibited in sport. No trial has compared them directly. [1] [2] [4] [5] [6] [7] [8]
How do cagrilintide and pramlintide compare?
| Dimension | Cagrilintide | Pramlintide |
|---|---|---|
| Molecule and duration [1] [7] | Acylated long acting amylin analog that binds albumin for once weekly dosing. | Human amylin with three proline substitutions to stop aggregation; short acting, injected immediately before each major meal. |
| Approved or studied use [1] [2] [7] | Studied for chronic weight management, alone and combined with semaglutide 2.4 mg (CagriSema). No approved use. | FDA approved as an adjunct to mealtime insulin in type 1 and type 2 diabetes when glucose is not controlled. Weight loss is off label. |
| Weight loss evidence [1] [2] [5] [6] | Phase 2 (706 adults, 26 weeks): 6.0% to 10.8% across 0.3 to 4.5 mg versus 3.0% on placebo. With semaglutide: 20.4% versus 3.0% at 68 weeks in REDEFINE 1. | Obesity phase 2 (204 adults, 16 weeks): about 3.6 kg placebo corrected loss at up to 240 ug three times daily. In insulin treated type 2 diabetes: minus 1.4 kg versus a 0.7 kg gain over 52 weeks. |
| Glucose lowering evidence [3] [4] [5] | Phase 2 in type 2 diabetes (92 adults, 32 weeks) tested it only in combination with semaglutide, with clinically relevant HbA1c improvement. | Type 1 diabetes: HbA1c down about 0.4 versus 0.1 points (480 adults, 52 weeks). Type 2 diabetes on insulin: 0.62 versus 0.22 points (656 adults, 52 weeks). |
| Key safety concerns [1] [7] | Nausea in 20% to 47% across doses versus 18% on placebo; long term safety and outcomes not yet reported. | Boxed warning for severe insulin induced hypoglycemia within 3 hours of injection; mealtime insulin is cut by 50% at start. Nausea in 28% to 48% in trials. Contraindicated in gastroparesis and hypoglycemia unawareness. |
| Dosing [1] [2] [7] | Trial regimens only: once weekly subcutaneous, escalated to 0.3 to 4.5 mg alone or 2.4 mg with semaglutide. | Symlin label: type 1 diabetes 15 ug before meals titrated to 30 or 60 ug; type 2 diabetes 60 ug titrated to 120 ug before meals. |
| Regulatory and compounding status [7] [8] | Not FDA approved; not on the 503A bulks list and not a component of an approved drug, so it cannot be compounded. | FDA approved (Symlin, March 2005). Not in shortage, so compounding is limited to documented patient specific need. |
| WADA status [9] | Prohibited at all times under section S0 (non-approved substances). | Not on the WADA Prohibited List. |
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | Cagrilintide | Pramlintide |
|---|---|---|
| Class | Investigational long acting amylin analog (acylated, once weekly), developed alone and in fixed combination with semaglutide 2.4 mg | Synthetic 37 amino acid analog of human amylin (three proline substitutions to prevent aggregation) |
| What it is | Experimental weekly copy of the appetite hormone amylin: 10.8% weight loss alone at 26 weeks and 20.4% with semaglutide at 68 weeks; not FDA approved. | FDA approved lab-made amylin used with mealtime insulin; lowers HbA1c about 0.3 to 0.4 points more than placebo, modest weight loss, boxed low sugar warning. |
| Evidence | Evidence: Human RCT evidence | Evidence: Human RCT evidence |
| FDA status | Regulatory: Not eligible for compounding | Regulatory: FDA approved |
| Compounding | Not FDA approved as of the last verification date, either alone or in the fixed combination with semaglutide. Because cagrilintide is not a component of an approved drug, has no USP monograph, and is not on the 503A bulks list, it cannot lawfully be compounded. Any product sold as cagrilintide or CagriSema outside a clinical trial is an unapproved drug. Check FDA for the status of any marketing application before relying on this record. | FDA approved product (Symlin, March 2005) for type 1 and type 2 diabetes in patients using mealtime insulin who have not achieved glucose control. It is prescription only. Because an approved product is available and not in shortage, compounding is not permitted except for a documented patient specific clinical need. Pramlintide is not on any FDA compounding bulks list and is not sold through peptide vendors in any meaningful way. |
| WADA | WADA: WADA prohibited | WADA: Not WADA prohibited |
| Routes | Subcutaneous injection once weekly (clinical trials only) | Subcutaneous injection before major meals (pen device) |
| Typical cost | Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | List price is well over 1,000 USD per month for SymlinPen at typical doses; commercial insurance copays vary and coverage often requires prior authorization. Prices verified on the last verified date. |
| Last verified |
Has cagrilintide been tested directly against pramlintide?
No published trial has compared cagrilintide and pramlintide directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do cagrilintide and pramlintide cost?
| Dimension | Cagrilintide | Pramlintide |
|---|---|---|
| Typical cost | Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | List price is well over 1,000 USD per month for SymlinPen at typical doses; commercial insurance copays vary and coverage often requires prior authorization. Prices verified on the last verified date. |
| Price detail | Price index in progress | Price index in progress |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
Frequently asked questions
Are cagrilintide and pramlintide the same kind of drug?
Yes, both mimic amylin, a hormone released with insulin that slows stomach emptying, suppresses glucagon after meals, and increases fullness. Pramlintide is short acting and taken before meals; cagrilintide is engineered for once weekly dosing. [1] [7]
Can pramlintide be used for weight loss instead of cagrilintide?
Not on label. Pramlintide is approved only as an add-on to mealtime insulin. An off label obesity trial found about 3.6 kg placebo corrected weight loss over 16 weeks at doses up to 240 ug three times daily, far less than cagrilintide's 10.8% at 26 weeks. [1] [6] [7]
Why does pramlintide have a boxed warning?
Because combined with mealtime insulin it can cause severe hypoglycemia, usually within 3 hours of the injection. The label requires cutting mealtime insulin by 50% when starting and excludes people with hypoglycemia unawareness. [7]
Can I get cagrilintide legally?
Only in a registered clinical trial. It is not FDA approved and is not on the 503A bulks list, so pharmacies cannot compound it; products sold as research chemicals are not lawful for human use. [8]
Is either banned in sport?
Cagrilintide is prohibited at all times under WADA section S0 because it is not approved. Pramlintide is not on the WADA Prohibited List. [9]
Conditions studied
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. Lancet 2021PubMed 34798060, 2021
- [2]Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med 2025 (REDEFINE 1)PubMed 40544433, 2025
- [3]Frias JP et al. Co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes: a phase 2 trial. Lancet 2023PubMed 37364590, 2023
- [4]Whitehouse F et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002PubMed 11919132, 2002
- [5]Hollander PA et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003PubMed 12610038, 2003
- [6]Aronne L et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 2007PubMed 17504894, 2007
- [7]FDA prescribing information for Symlin (pramlintide acetate) injection, via DailyMedFDA
- [8]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA
- [9]WADA Prohibited List, including section S0 non-approved substancesWADA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 22). Cagrilintide vs pramlintide: evidence, cost, and legality. https://peptideagent.ai/compare/cagrilintide-vs-pramlintide- HTML link
<a href="https://peptideagent.ai/compare/cagrilintide-vs-pramlintide">Cagrilintide vs pramlintide: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.